Onabotulinumtoxin  ||| S:0 E:18 ||| NNP
A  ||| S:18 E:20 ||| NNP
in  ||| S:20 E:23 ||| IN
the  ||| S:23 E:27 ||| DT
treatment  ||| S:27 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
chronic  ||| S:40 E:48 ||| JJ
migraine  ||| S:48 E:57 ||| JJ
INTRODUCTION ||| S:57 E:69 ||| NNP
.  ||| S:69 E:71 ||| .
Chronic  ||| S:71 E:79 ||| JJ
migraine  ||| S:79 E:88 ||| NN
is  ||| S:88 E:91 ||| VBZ
the  ||| S:91 E:95 ||| DT
most  ||| S:95 E:100 ||| RBS
frequent  ||| S:100 E:109 ||| JJ
complication  ||| S:109 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
migraine ||| S:125 E:133 ||| NN
.  ||| S:133 E:135 ||| .
Its  ||| S:135 E:139 ||| PRP$
management  ||| S:139 E:150 ||| NN
is  ||| S:150 E:153 ||| VBZ
complex  ||| S:153 E:161 ||| JJ
and  ||| S:161 E:165 ||| CC
difficult ||| S:165 E:174 ||| JJ
,  ||| S:174 E:176 ||| ,
and  ||| S:176 E:180 ||| CC
is  ||| S:180 E:183 ||| VBZ
based  ||| S:183 E:189 ||| VBN
essentially  ||| S:189 E:201 ||| RB
on  ||| S:201 E:204 ||| IN
preventive  ||| S:204 E:215 ||| JJ
measures ||| S:215 E:223 ||| NNS
.  ||| S:223 E:225 ||| .
AIM ||| S:225 E:228 ||| NN
.  ||| S:228 E:230 ||| .
To  ||| S:230 E:233 ||| TO
analyse  ||| S:233 E:241 ||| VB
the  ||| S:241 E:245 ||| DT
development  ||| S:245 E:257 ||| NN
of  ||| S:257 E:260 ||| IN
the  ||| S:260 E:264 ||| DT
use  ||| S:264 E:268 ||| NN
of  ||| S:268 E:271 ||| IN
Onabotulinumtoxin  ||| S:271 E:289 ||| NNP
A  ||| S:289 E:291 ||| NNP
( ||| S:291 E:292 ||| -LRB-
OnabotA ||| S:292 E:299 ||| NNP
)  ||| S:299 E:301 ||| -RRB-
in  ||| S:301 E:304 ||| IN
migraine ||| S:304 E:312 ||| NN
,  ||| S:312 E:314 ||| ,
especially  ||| S:314 E:325 ||| RB
in  ||| S:325 E:328 ||| IN
its  ||| S:328 E:332 ||| PRP$
chronic  ||| S:332 E:340 ||| JJ
form ||| S:340 E:344 ||| NN
,  ||| S:344 E:346 ||| ,
the  ||| S:346 E:350 ||| DT
method  ||| S:350 E:357 ||| NN
of  ||| S:357 E:360 ||| IN
administration ||| S:360 E:374 ||| NN
,  ||| S:374 E:376 ||| ,
its  ||| S:376 E:380 ||| PRP$
mechanism  ||| S:380 E:390 ||| NN
of  ||| S:390 E:393 ||| IN
action ||| S:393 E:399 ||| NN
,  ||| S:399 E:401 ||| ,
its  ||| S:401 E:405 ||| PRP$
safety  ||| S:405 E:412 ||| NN
profile  ||| S:412 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
its  ||| S:424 E:428 ||| PRP$
possible  ||| S:428 E:437 ||| JJ
indications  ||| S:437 E:449 ||| NNS
in  ||| S:449 E:452 ||| IN
clinical  ||| S:452 E:461 ||| JJ
practice ||| S:461 E:469 ||| NN
.  ||| S:469 E:471 ||| .
DEVELOPMENT ||| S:471 E:482 ||| NNP
.  ||| S:482 E:484 ||| .
The  ||| S:484 E:488 ||| DT
study  ||| S:488 E:494 ||| NN
conducts  ||| S:494 E:503 ||| VBZ
a  ||| S:503 E:505 ||| DT
thorough  ||| S:505 E:514 ||| JJ
review  ||| S:514 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
all  ||| S:524 E:528 ||| PDT
the  ||| S:528 E:532 ||| DT
clinical  ||| S:532 E:541 ||| JJ
trials  ||| S:541 E:548 ||| NNS
in  ||| S:548 E:551 ||| IN
the  ||| S:551 E:555 ||| DT
literature  ||| S:555 E:566 ||| NN
that  ||| S:566 E:571 ||| WDT
have  ||| S:571 E:576 ||| VBP
used  ||| S:576 E:581 ||| VBN
OnabotA  ||| S:581 E:589 ||| JJ
in  ||| S:589 E:592 ||| IN
the  ||| S:592 E:596 ||| DT
prevention  ||| S:596 E:607 ||| NN
of  ||| S:607 E:610 ||| IN
migraine ||| S:610 E:618 ||| NN
,  ||| S:618 E:620 ||| ,
both  ||| S:620 E:625 ||| DT
in  ||| S:625 E:628 ||| IN
its  ||| S:628 E:632 ||| PRP$
episodic  ||| S:632 E:641 ||| NN
and  ||| S:641 E:645 ||| CC
its  ||| S:645 E:649 ||| PRP$
chronic  ||| S:649 E:657 ||| JJ
forms ||| S:657 E:662 ||| NNS
,  ||| S:662 E:664 ||| ,
and  ||| S:664 E:668 ||| CC
the  ||| S:668 E:672 ||| DT
outcomes  ||| S:672 E:681 ||| NN
in  ||| S:681 E:684 ||| IN
the  ||| S:684 E:688 ||| DT
chronic  ||| S:688 E:696 ||| JJ
form  ||| S:696 E:701 ||| NN
are  ||| S:701 E:705 ||| VBP
analysed  ||| S:705 E:714 ||| VBN
in  ||| S:714 E:717 ||| IN
detail ||| S:717 E:723 ||| NN
.  ||| S:723 E:725 ||| .
CONCLUSIONS ||| S:725 E:736 ||| NNS
.  ||| S:736 E:738 ||| .
In  ||| S:738 E:741 ||| IN
studies  ||| S:741 E:749 ||| NNS
in  ||| S:749 E:752 ||| IN
phase  ||| S:752 E:758 ||| NN
III ||| S:758 E:761 ||| NNP
,  ||| S:761 E:763 ||| ,
OnabotA  ||| S:763 E:771 ||| NNP
has  ||| S:771 E:775 ||| VBZ
proved  ||| S:775 E:782 ||| VBN
to  ||| S:782 E:785 ||| TO
be  ||| S:785 E:788 ||| VB
effective  ||| S:788 E:798 ||| JJ
in  ||| S:798 E:801 ||| IN
the  ||| S:801 E:805 ||| DT
treatment  ||| S:805 E:815 ||| NN
of  ||| S:815 E:818 ||| IN
patients  ||| S:818 E:827 ||| NNS
with  ||| S:827 E:832 ||| IN
chronic  ||| S:832 E:840 ||| JJ
migraine ||| S:840 E:848 ||| NN
,  ||| S:848 E:850 ||| ,
with  ||| S:850 E:855 ||| IN
significant  ||| S:855 E:867 ||| JJ
reductions  ||| S:867 E:878 ||| NNS
in  ||| S:878 E:881 ||| IN
the  ||| S:881 E:885 ||| DT
mean  ||| S:885 E:890 ||| JJ
frequency  ||| S:890 E:900 ||| NN
of  ||| S:900 E:903 ||| IN
days  ||| S:903 E:908 ||| NNS
with  ||| S:908 E:913 ||| IN
headaches ||| S:913 E:922 ||| NNS
,  ||| S:922 E:924 ||| ,
the  ||| S:924 E:928 ||| DT
number  ||| S:928 E:935 ||| NN
of  ||| S:935 E:938 ||| IN
headache  ||| S:938 E:947 ||| JJ
episodes ||| S:947 E:955 ||| NNS
,  ||| S:955 E:957 ||| ,
the  ||| S:957 E:961 ||| DT
days  ||| S:961 E:966 ||| NNS
with  ||| S:966 E:971 ||| IN
migraine  ||| S:971 E:980 ||| NN
or  ||| S:980 E:983 ||| CC
the  ||| S:983 E:987 ||| DT
proportion  ||| S:987 E:998 ||| NN
of  ||| S:998 E:1001 ||| IN
patients  ||| S:1001 E:1010 ||| NNS
with  ||| S:1010 E:1015 ||| IN
severe  ||| S:1015 E:1022 ||| JJ
disability ||| S:1022 E:1032 ||| NN
,  ||| S:1032 E:1034 ||| ,
in  ||| S:1034 E:1037 ||| IN
addition  ||| S:1037 E:1046 ||| NN
to  ||| S:1046 E:1049 ||| TO
other  ||| S:1049 E:1055 ||| JJ
parameters ||| S:1055 E:1065 ||| NNS
.  ||| S:1065 E:1067 ||| .
It  ||| S:1067 E:1070 ||| PRP
is  ||| S:1070 E:1073 ||| VBZ
also  ||| S:1073 E:1078 ||| RB
effective  ||| S:1078 E:1088 ||| JJ
in  ||| S:1088 E:1091 ||| IN
the  ||| S:1091 E:1095 ||| DT
subgroup  ||| S:1095 E:1104 ||| NN
of  ||| S:1104 E:1107 ||| IN
patients  ||| S:1107 E:1116 ||| NNS
with  ||| S:1116 E:1121 ||| IN
symptomatic  ||| S:1121 E:1133 ||| JJ
headache  ||| S:1133 E:1142 ||| JJ
due  ||| S:1142 E:1146 ||| JJ
to  ||| S:1146 E:1149 ||| TO
medication  ||| S:1149 E:1160 ||| VB
abuse ||| S:1160 E:1165 ||| NN
.  ||| S:1165 E:1167 ||| .
OnabotA  ||| S:1167 E:1175 ||| NNP
has  ||| S:1175 E:1179 ||| VBZ
proved  ||| S:1179 E:1186 ||| VBN
to  ||| S:1186 E:1189 ||| TO
be  ||| S:1189 E:1192 ||| VB
safe  ||| S:1192 E:1197 ||| JJ
and  ||| S:1197 E:1201 ||| CC
well  ||| S:1201 E:1206 ||| RB
tolerated  ||| S:1206 E:1216 ||| VBN
in  ||| S:1216 E:1219 ||| IN
this  ||| S:1219 E:1224 ||| DT
indication ||| S:1224 E:1234 ||| NN
,  ||| S:1234 E:1236 ||| ,
with  ||| S:1236 E:1241 ||| IN
foreseeable ||| S:1241 E:1252 ||| JJ
,  ||| S:1252 E:1254 ||| ,
usually  ||| S:1254 E:1262 ||| RB
mild  ||| S:1262 E:1267 ||| JJ
or  ||| S:1267 E:1270 ||| CC
moderate ||| S:1270 E:1278 ||| JJ
,  ||| S:1278 E:1280 ||| ,
transitory  ||| S:1280 E:1291 ||| JJ
side  ||| S:1291 E:1296 ||| NN
effects ||| S:1296 E:1303 ||| NNS
.  ||| S:1303 E:1305 ||| .
In  ||| S:1305 E:1308 ||| IN
sum ||| S:1308 E:1311 ||| NN
,  ||| S:1311 E:1313 ||| ,
OnabotA  ||| S:1313 E:1321 ||| NNP
is  ||| S:1321 E:1324 ||| VBZ
a  ||| S:1324 E:1326 ||| DT
safe ||| S:1326 E:1330 ||| JJ
,  ||| S:1330 E:1332 ||| ,
well-tolerated  ||| S:1332 E:1347 ||| JJ
alternative  ||| S:1347 E:1359 ||| NN
in  ||| S:1359 E:1362 ||| IN
the  ||| S:1362 E:1366 ||| DT
preventive  ||| S:1366 E:1377 ||| JJ
treatment  ||| S:1377 E:1387 ||| NN
of  ||| S:1387 E:1390 ||| IN
chronic  ||| S:1390 E:1398 ||| JJ
migraine ||| S:1398 E:1406 ||| NN
.  ||| S:1406 E:1408 ||| .
